ArticlePloS one2015
Deregulated expression of Aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Thyroid and renal cancers: A bidirectional association.Frontiers in oncology · 2022Pooled it
- Differential diagnosis of thyroid nodule capsules using random forest guided selection of image features.Scientific reports · 2022Article
- Aurora kinase a promotes the progression of papillary thyroid carcinoma by activating the mTORC2-AKT signalling pathway.Cell & bioscience · 2022Article
- Intraoperative Neuromonitoring and Optical Magnification in the Prevention of Recurrent Laryngeal Nerve Injuries during Total Thyroidectomy.Medicina (Kaunas, Lithuania) · 2022Article
- Is Melanoma Progression Affected by Thyroid Diseases?International journal of molecular sciences · 2022Review
- Risk Factors for Cervical Lymph Node Metastasis in Middle Eastern Papillary Thyroid Microcarcinoma.Journal of clinical medicine · 2022Article
- Review
- Article
- Molecular features of aggressive thyroid cancer.Frontiers in oncology · 2022Review
- Association between hashimoto thyroiditis and differentiated thyroid cancer: A single-center experience.Frontiers in oncology · 2022Article
- Health-related quality of life in long-term differentiated thyroid cancer survivors: A cross-sectional Tunisian-based study.Frontiers in endocrinology · 2022Article
- Plasma miR-323 as a Biomarker for Screening Papillary Thyroid Cancer From Healthy Controls.Frontiers in medicine · 2020Article
- Serum miR-22 may be a biomarker for papillary thyroid cancer.Oncology letters · 2019Article
- Role of prophylactic central neck dissection in clinically node-negative differentiated thyroid cancer: assessment of the risk of regional recurrence.Updates in surgery · 2017Article
- Minimally invasive video-assisted thyroidectomy and transoral video-assisted thyroidectomy: A comparison of two systematic reviews.Journal of minimal access surgeryReview
- Incidental thyroid carcinomas. A retrospective study.Il Giornale di chirurgiaArticle
- Early discharge after total thyroidectomy: a retrospective feasibility study.Il Giornale di chirurgiaArticle
- Differentiated thyroid cancer: feasibility of loboisthmectomy in an endemic region.Il Giornale di chirurgiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A number of reports indicated that Aurora-A or Aurora-B overexpression represented a negative prognostic factor in several human malignancies. In thyroid cancer tissues a deregulated expression of Aurora kinases has been also demonstrated, but no information regarding its possible prognostic role in differentiated thyroid cancer is available. Here, we evaluated Aurora-A and Aurora-B mRNA expression and its prognostic relevance in a series of 87 papillary thyroid cancers (PTC), with a median follow-up of 63 months. The analysis of Aurora-A and Aurora-B mRNA levels in PTC tissues, compared to normal matched tissues, revealed that their expression was either up- or down-regulated in the majority of cancer tissues. In particular, Aurora-A and Aurora-B mRNA levels were altered, respectively, in 55 (63.2%) and 79 (90.8%) out of the 87 PTC analyzed.A significant positive correlation between Aurora-A and Aurora-B mRNAs was observed (p=0.001). The expression of both Aurora genes was not affected by the BRAFV600E mutation. Univariate, multivariate and Kaplan-Mayer analyses documented the lack of association between Aurora-A or Aurora-B expression and clinicopathological parameters such as gender, age, tumor size, histology, TNM stage, lymph node metastasis and BRAF status as well as disease recurrences or disease-free interval. Only Aurora-B mRNA was significantly higher in T(3-4) tissues, with respect to T(1-2) PTC tissues. The data reported here demonstrate that the expression of Aurora kinases is deregulated in the majority of PTC tissues, likely contributing to PTC progression. However, differently from other human solid cancers, detection of Aurora-A or Aurora-B mRNAs is not a prognostic biomarker in PTC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.